BIVI To Launch Oral Bordetella Vaccine

Posted: April 3, 2012, 6:00 p.m. EDT



Published:

Boehringer Ingelheim Vetmedica Inc. received U.S. Food and Drug Administration approval for an oral vaccine that aids in the protection against the primary pathogen of canine infectious respiratory disease in dogs.

The vaccine, called Bronchi-Shield Oral, is the first live, avirulent Bordetella bronchiseptica vaccine licensed to be administered orally to dogs, the St. Joseph, Mo.-based company said.

“Doctors told us they like intranasal vaccines because they provide optimal immune responses, but doctors and their patients dislike having these vaccines given in the nose,” said Arne Zislin, VMD, technical manager veterinarian for BIVI. “So we’ve developed an easy-to-administer oral vaccine that is mucosally absorbed.”

The vaccine proved to provide protection against B. bronchiseptica in a challenge study, according to Zislin.

Administration requires veterinarians to instill a 1.0 mL dose into the buccal cavity of healthy dogs eight weeks of age or older, and the company recommends annual revaccination.

B. bronchiseptica vaccines are considered noncore by the American Animal Hospital Association 2011 Vaccination Guidelines, but BIVI says many dogs are at risk of infection.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

K-State Unveils Test for New Dog Flu Strain

The Veterinary Diagnostic Laboratory uses sequencing to identify H3N2 and help in the search for a vaccine.

MSU Names Co-Directors of Veterinary Technology Program

Jolynne Judge, LVT, and Helen Mayer, LVT, bring decades of first-hand experience to the position.

Pets Best Reaches $100 Million in Payouts

The milestone is a victory for pets and a defeat for economic euthanasia, the insurer states.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module